Owkin: Federated Learning Meets Drug Discovery
Owkin is a Franco-American biotech company valued at $1 billion, using federated learning (AI that trains on distributed hospital data without centralizing sensitive records) to accelerate drug discovery and precision medicine.
Key Metrics
| Metric | Value |
|---|---|
| Valuation | $1 billion |
| Total Raised | $300M+ |
| Hospital Partners | 30+ (including AP-HP, Mount Sinai) |
| Pharma Partners | Sanofi, BMS, Roche |
| AI Models Deployed | Diagnostic + prognostic pathology |
Technology Breakthrough
Owkin’s federated learning platform enables AI training across hospital networks without moving patient data — solving the fundamental privacy/scale tradeoff in medical AI. The company’s MSIntuit diagnostic tool (detecting microsatellite instability in colorectal cancer from H&E slides) is CE-marked and deployed clinically.
Pharma Revenue Model
Owkin sells AI-powered insights to pharmaceutical companies: biomarker discovery for clinical trial design, patient stratification for drug development, and real-world evidence generation. Partnerships with Sanofi and Bristol Myers Squibb generate multi-year revenue contracts. The company represents the intersection of France 2030 health and AI investment.